Urogen Pharma logo

Urogen Pharma Share Price Today

(NASDAQ: URGN)

Urogen Pharma share price is $10.17 & ₹884.47 as on 6 Mar 2025, 2.30 'hrs' IST

$10.17

▲

0.57

(5.94%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Urogen Pharma share price in Dollar and Rupees. Guide to invest in Urogen Pharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Urogen Pharma, along with analyst recommendations, forecasts, and comprehensive financials.

Urogen Pharma share price movements

  • Today's Low: $9.88
    Today's High: $10.33

    Day's Volatility :4.31%

  • 52 Weeks Low: $9.03
    52 Weeks High: $20.70

    52 Weeks Volatility :56.38%

Urogen Pharma (URGN) Returns

PeriodUrogen Pharma LtdSector (Health Care)Index (Russel 2000)
3 Months
-16.71%
3.7%
0.0%
6 Months
-25.93%
-2.8%
0.0%
1 Year
-43.66%
2.5%
0.0%
3 Years
63.5%
12.9%
-11.6%

Urogen Pharma (URGN) Key Statistics

in dollars & INR

Previous Close
$9.6
Open
$9.67
Today's High
$10.325
Today's Low
$9.88
Market Capitalization
$405.1M
Today's Volume
$468.5K
52 Week High
$20.7
52 Week Low
$9.03
Revenue TTM
$89.4M
EBITDA
$-83.3M
Earnings Per Share (EPS)
$-3.13
Profit Margin
-129.11%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-1481.26%

How to invest in Urogen Pharma Stock (URGN) from India?

It is very easy for Indian residents to invest directly in Urogen Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Urogen Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Urogen Pharma or URGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Urogen Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Urogen Pharma shares which would translate to 0.086 fractional shares of Urogen Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Urogen Pharma, in just a few clicks!

Returns in Urogen Pharma (URGN) for Indian investors in Rupees

The Urogen Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Urogen Pharma investment value today

Current value as on today

₹61,292

Returns

₹38,708

(-38.71%)

Returns from Urogen Pharma Stock

₹43,657 (-43.66%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Urogen Pharma (URGN)

-20%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Urogen Pharma Stock from India on INDmoney has decreased by -20% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Urogen Pharma

  • Morgan Stanley - Brokerage Accounts

    5.17%

  • Vestal Point Capital LP

    3.86%

  • Jefferies Financial Group Inc

    2.29%

  • Woodline Partners LP

    0.72%

  • SUPERSTRING CAPITAL MANAGEMENT LP

    0.71%

  • Cormorant Asset Management, LLC

    0.71%

Analyst Recommendation on Urogen Pharma

Buy

    81%Buy

    18%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Urogen Pharma(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Urogen Pharma Stock (URGN)

What analysts predicted

Upside of 261.01%

Target:

$36.71

Current:

$10.17

Insights on Urogen Pharma Stock (Ticker Symbol: URGN)

  • Price Movement

    In the last 7 days, URGN stock has moved up by 9.5%

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 18.78M → 25.20M (in $), with an average increase of 13.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -33.40M → -23.67M (in $), with an average increase of 41.1% per quarter

  • URGN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 110.2%

  • Price to Sales

    ForURGN every $1 of sales, investors are willing to pay $4.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

URGN Urogen Pharma Financials in INR & Dollars

FY18Y/Y Change
Revenue
$1.1M
↓ 86.17%
Net Income
$-75.7M
↑ 278.28%
Net Profit Margin
-6.7K%
↓ 6462.02%
FY19Y/Y Change
Revenue
$18.0K
↓ 98.4%
Net Income
$-100.5M
↑ 32.88%
Net Profit Margin
-558.5K%
↓ 551792.82%
FY20Y/Y Change
Revenue
$11.8M
↑ 65450.0%
Net Income
$-128.5M
↑ 27.81%
Net Profit Margin
-1.1K%
↑ 557411.06%
FY21Y/Y Change
Revenue
$48.0M
↑ 307.17%
Net Income
$-110.8M
↓ 13.75%
Net Profit Margin
-230.67%
↑ 858.27%
FY22Y/Y Change
Revenue
$64.4M
↑ 33.96%
Net Income
$-109.2M
↓ 1.5%
Net Profit Margin
-169.62%
↑ 61.05%
FY23Y/Y Change
Revenue
$82.7M
↑ 28.52%
Net Income
$-102.2M
↓ 6.34%
Net Profit Margin
-123.61%
↑ 46.01%
Q2 FY23Q/Q Change
Revenue
$21.1M
↑ 22.96%
Net Income
$-24.1M
↓ 20.11%
Net Profit Margin
-114.18%
↑ 61.56%
Q3 FY23Q/Q Change
Revenue
$20.9M
↓ 1.36%
Net Income
$-21.9M
↓ 9.35%
Net Profit Margin
-104.93%
↑ 9.25%
Q4 FY23Q/Q Change
Revenue
$23.5M
↑ 12.84%
Net Income
$-26.0M
↑ 18.91%
Net Profit Margin
-110.57%
↓ 5.64%
Q1 FY24Q/Q Change
Revenue
$18.8M
↓ 20.18%
Net Income
$-32.3M
↑ 24.1%
Net Profit Margin
-171.91%
↓ 61.34%
Q2 FY24Q/Q Change
Revenue
$21.8M
↑ 16.33%
Net Income
$-33.4M
↑ 3.46%
Net Profit Margin
-152.89%
↑ 19.02%
Q3 FY24Q/Q Change
Revenue
$25.2M
↑ 15.36%
Net Income
$-23.7M
↓ 29.13%
Net Profit Margin
-93.93%
↑ 58.96%
FY18Y/Y Change
Profit
$-675.0K
↓ 108.93%
FY19Y/Y Change
Profit
$18.0K
↓ 102.67%
FY20Y/Y Change
Profit
$10.8M
↑ 59844.44%
FY21Y/Y Change
Profit
$42.9M
↑ 297.45%
FY22Y/Y Change
Profit
$56.7M
↑ 32.22%
FY23Y/Y Change
Profit
$73.4M
↑ 29.36%
Q2 FY23Q/Q Change
Profit
$18.7M
↑ 25.25%
Q3 FY23Q/Q Change
Profit
$18.5M
↓ 1.13%
Q4 FY23Q/Q Change
Profit
$21.2M
↑ 14.93%
Q1 FY24Q/Q Change
Profit
$17.1M
↓ 19.73%
Q2 FY24Q/Q Change
Profit
$19.6M
↑ 15.05%
Q3 FY24Q/Q Change
Profit
$22.8M
↑ 15.96%
FY18Y/Y Change
Operating Cash Flow
$-37.3M
↑ 290.07%
Investing Cash Flow
$35.3M
↓ 197.27%
Financing Cash Flow
$66.4M
↑ 7.85%
FY19Y/Y Change
Operating Cash Flow
$-71.0M
↑ 90.22%
Investing Cash Flow
$-145.6M
↓ 512.6%
Financing Cash Flow
$165.3M
↑ 148.79%
FY20Y/Y Change
Operating Cash Flow
$-105.9M
↑ 49.1%
Investing Cash Flow
$93.2M
↓ 164.04%
Financing Cash Flow
$16.5M
↓ 90.0%
FY21Y/Y Change
Operating Cash Flow
$-84.9M
↓ 19.83%
Investing Cash Flow
$4.1M
↓ 95.64%
Financing Cash Flow
$72.3M
↑ 337.58%
FY22Y/Y Change
Operating Cash Flow
$-87.6M
↑ 3.14%
Investing Cash Flow
$1.1M
↓ 73.95%
Financing Cash Flow
$97.1M
↑ 34.31%
Q2 FY23Q/Q Change
Operating Cash Flow
$-20.3M
↓ 21.44%
Investing Cash Flow
$3.7M
↓ 40.67%
Financing Cash Flow
$143.0K
↓ 78.69%

Urogen Pharma Technicals Summary

Sell

Neutral

Buy

Urogen Pharma is currently in a neutral trading position according to technical analysis indicators.

Urogen Pharma (URGN) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Urogen Pharma Ltd logo
Urogen Pharma Ltd
-10.0%
-25.93%
-43.66%
63.5%
-62.36%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
Beone Medicines Ltd
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Urogen Pharma Ltd logo
Urogen Pharma Ltd
NA
NA
0.0
-3.13
-14.81
-0.21
NA
0.61
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Urogen Pharma Ltd logo
Urogen Pharma Ltd
Buy
$405.1M
-62.36%
NA
-129.11%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
Buy
$31.4B
126.66%
NA
-12.37%

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Organization
Urogen Pharma
Employees
217
CEO
Ms. Elizabeth A. Barrett
Industry
Health Technology

Management People of Urogen Pharma

NameTitle
Ms. Elizabeth A. Barrett
President, CEO & Director
Mr. Jason Drew Smith J.D.
General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Mark P. Schoenberg M.D.
Chief Medical Officer
Mr. Christopher Degnan CPA
Chief Financial Officer
Mr. Vincent I. Perrone
Senior Director of Investor Relations
Mr. Bryon Wornson
Executive Vice President of Talent, Advocacy & Communications
Dr. Marina Konorty Ph.D.
Executive Vice President of Research & Development and Technical Operations
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D.
Chief Business Officer
Mr. Michael J. Louie M.D., M.P.H., M.Sc.
Senior Vice President of Medical Affairs & Clinical Development

Important FAQs about investing in URGN Stock from India :

What is Urogen Pharma share price today?

Urogen Pharma share price today stands at $10.17, Open: $9.67 ; Previous Close: $9.60 ; High: $10.33 ; Low: $9.88 ; 52 Week High: $20.70 ; 52 Week Low: $9.03.

The stock opens at $9.67, after a previous close of $9.60. The stock reached a daily high of $10.33 and a low of $9.88, with a 52-week high of $20.70 and a 52-week low of $9.03.

Can Indians buy Urogen Pharma shares?

Yes, Indians can invest in the Urogen Pharma (URGN) from India.

With INDmoney, you can buy Urogen Pharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Urogen Pharma at zero transaction cost.

How can I buy Urogen Pharma shares from India?

It is very easy to buy Urogen Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Urogen Pharma (URGN) be purchased?

Yes, you can buy fractional shares of Urogen Pharma with INDmoney app.

What are the documents required to start investing in Urogen Pharma stocks?

To start investing in Urogen Pharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Urogen Pharma Stock (URGN)?

Today’s highest price of Urogen Pharma (URGN) is $10.33.

Today’s lowest price of Urogen Pharma (URGN) is $9.88.

What is today's market capitalisation of Urogen Pharma?

Today's market capitalisation of Urogen Pharma URGN is 405.1M

What is the 52 Week High and Low Range of Urogen Pharma Stock (URGN)?

  • 52 Week High

    $20.70

  • 52 Week Low

    $9.03

What are the historical returns of Urogen Pharma (URGN)?

  • 1 Month Returns

    -10%

  • 3 Months Returns

    -25.93%

  • 1 Year Returns

    -43.66%

  • 5 Years Returns

    -62.36%

Who is the Chief Executive Officer (CEO) of Urogen Pharma ?

Ms. Elizabeth A. Barrett is the current Chief Executive Officer (CEO) of Urogen Pharma.